1,561
Views
5
CrossRef citations to date
0
Altmetric
Basic Research

Quantity of phenibut in dietary supplements before and after FDA warnings

, , , &
Pages 486-488 | Received 01 Jun 2021, Accepted 21 Aug 2021, Published online: 22 Sep 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Pieter A. Cohen, Bharathi Avula & Ikhlas Khan. (2022) The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements. Clinical Toxicology 60:10, pages 1156-1158.
Read now
Neta Cohen, Suzanne Schuh & Yaron Finkelstein. (2022) Response to the comment on “pediatric cannabis intoxication trends in the pre and post-legalization era”. Clinical Toxicology 60:4, pages 545-546.
Read now

Articles from other publishers (3)

Karol Jędrejko, Oliver Catlin, Timothy Stewart, Ashley Anderson, Bożena Muszyńska & Don H. Catlin. (2023) Unauthorized ingredients in “nootropic” dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents. Drug Testing and Analysis 15:8, pages 803-839.
Crossref
Ethan Wainblat, Jeremy Weleff & Akhil Anand. (2023) Management of Phenibut Use Disorder and Withdrawal in a Geriatric Patient. The American Journal of Geriatric Psychiatry 31:1, pages 67-74.
Crossref
Perla C. Reyes Fernandez, Christian S. Wright, Stuart J. Warden, Julia Hum, Mary C. Farach-Carson & William R. Thompson. (2022) Effects of Gabapentin and Pregabalin on Calcium Homeostasis: Implications for Physical Rehabilitation of Musculoskeletal Tissues. Current Osteoporosis Reports 20:6, pages 365-378.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.